Evidence map›Paper›PMID 35711684›Full record

ReviewLancet regional health. Americas2022

2021 World Health Organization guideline on pharmacological treatment of hypertension: Policy implications for the region of the Americas.

Norm R C Campbell, Melanie Paccot Burnens, Paul K Whelton, Sonia Y Angell, Marc G Jaffe, Jennifer Cohn, Alfredo Espinosa Brito, Vilma Irazola, Jeffrey W Brettler, Edward J Roccella and 3 more

Open access · goldAbstract readReview
In one paragraph

Review in Lancet regional health. Americas, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 2 pooled it
16.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 2 syntheses or guidelines pooled it, 102 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Cost-effectiveness analysis of early antihypertensive treatment for hypertension detected at health screening.Hypertension research : official journal of the Japanese Society of Hypertension · 2026
    Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Investigating feature-engineered predictors for systolic blood pressure changes in an mHealth-based disease management program.Hypertension research : official journal of the Japanese Society of Hypertension · 2026
    Article
  9. Article
  10. Review
  11. Burden of hypertension-related diseases in Eastern Mediterranean region.Journal of Taibah University Medical Sciences · 2026
    Article
  12. GPER1 activation regulates renal purinergic P2YAmerican journal of physiology. Regulatory, integrative and comparative physiology · 2026
    Article
  13. Article
  14. New Insight Into Male Infertility: Deviation From Basic Tenets of Life.Oxidative medicine and cellular longevity · 2026
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 11 institutions in 5 countries.

Norm R C CampbellDepartment of Medicine, Physiology and Pharmacology and Community Health Sciences, Libin Cardiovascular Institute of Alberta, University of Calgary, North Tower, 9th Floor, 1403 - 29th Street NW, Calgary, AB T2N 2T9, Canada.
Melanie Paccot BurnensHead of the Department of Non-Communicable Diseases, Ministry of Health in Chile, Santiago, Chile.
Paul K WheltonDepartment of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, USA.
Sonia Y AngellDepartment of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
Marc G JaffeDepartment of Endocrinology, Kaiser Permanente San Francisco Medical Center, San Francisco, CA, USA.
Jennifer CohnDepartment of Internal Medicine, School of Medicine, University of Pennsylvania, Philadelphia, USA.
Alfredo Espinosa BritoDepartment of Internal Medicine, Hospital "Dr. Gustavo Aldereguía Lima", Cienfuegos, Cuba.
Vilma IrazolaDepartment of Research in Chronic Diseases, Center of Excellence for Cardiovascular Health, CESCAS, Institute for Clinical Effectiveness and Health Policy, IECS, Buenos Aires, Argentina.
Jeffrey W BrettlerDepartment of Health Systems Science, Southern California Permanente Medical Group, Los Angeles, California, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA, USA.
Edward J RoccellaUnited States National High Blood Pressure Education Program (Ret.) National Heart, Lung and Blood Institute National Institutes of Health Bethesda, MD, USA.
Javier Isaac Maldonado FigueredoPan American Health Organization, Colombia Office, USA.
Andres RosendeDepartment of Non-Communicable Diseases and Mental Health, Pan American Health Organization, Washington, DC, USA.
Pedro OrdunezDepartment of Non-Communicable Diseases and Mental Health, Pan American Health Organization, Washington, DC, USA.
World Health Organization Regional Office for the Americas · USColumbia University · USInstituto de Efectividad Clínica y Sanitaria · ARKaiser Permanente · USKaiser Permanente San Francisco Medical Center · USMinistry of Health · CLNational Institutes of Health · USTulane University · USUniversidad de Ciencias Médicas de Cienfuegos · CUUniversity of Calgary · CAUniversity of Pennsylvania · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiovascular disease (CVD) is the leading cause of death in the Americas and raised blood pressure accounts for over 50% of CVD. In the Americas over a quarter of adult women and four in ten adult men have hypertension and the diagnosis, treatment and control are suboptimal. In 2021, the World Health Organization (WHO) released an updated guideline for the pharmacological treatment of hypertension in adults. This policy paper highlights the facilitating role of the WHO Global HEARTS initiative and the HEARTS in the Americas initiative to catalyze the implementation of this guideline, provides specific policy advice for implementation, and emphasizes that an overarching strategic approach for hypertension control is needed. The authors urge health advocates and policymakers to prioritize the prevention and control of hypertension to improve the health and wellbeing of their populations and to reduce CVD health disparities within and between populations of the Americas.

Indexed as

Cardiovascular diseaseClinical guidelineHealth policyHealth servicesHigh blood pressureHypertensionPublic health

Identifiers

PMID35711684
PMCPMC9107389
OpenAlexW4214834440

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.